{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:35:38Z","timestamp":1791462938754,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European Alliance of Associations for Rheumatology","doi-asserted-by":"publisher","award":["QoC022"],"award-info":[{"award-number":["QoC022"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ero.2025.07.006","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T12:47:04Z","timestamp":1755953224000},"page":"210-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of systemic lupus erythematosus with kidney involvement: systematic literature review to inform the 2025 update of EULAR recommendations"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8832-7475","authenticated-orcid":false,"given":"Myrto","family":"Kostopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Scire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios T.","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Fanouriakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ero.2025.07.006_bib0001","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.006_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001263","article-title":"Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations","volume":"6","author":"Kostopoulou","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.ero.2025.07.006_bib0003","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ero.2025.07.006_bib0004","first-page":"187","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"2011","author":"Higgins","year":"2011","journal-title":"Cochrane Collab"},{"key":"10.1016\/j.ero.2025.07.006_bib0005","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"10.1016\/j.ero.2025.07.006_bib0006","first-page":"161","article-title":"Silent lupus nephritis: renal histopathological profile and early detection with urinary monocyte chemotactic protein 1","volume":"14","author":"Gouda","year":"2022","journal-title":"Open Access Rheumatol Res Rev"},{"key":"10.1016\/j.ero.2025.07.006_bib0007","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1093\/rheumatology\/keac067","article-title":"High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership","volume":"61","author":"Carlucci","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.ero.2025.07.006_bib0008","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.ekir.2020.09.007","article-title":"Low-level proteinuria in systemic lupus erythematosus","volume":"5","author":"Chedid","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ero.2025.07.006_bib0009","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/1319-2442.391894","article-title":"Levels of proteinuria and renal pathology in systemic lupus erythematosus patients","volume":"34","author":"Al Arfaj","year":"2023","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.ero.2025.07.006_bib0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4103\/1319-2442.389422","article-title":"Urinary sediments as predictors of the histopathology of lupus nephritis","volume":"33","author":"Gamaleldin","year":"2022","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.ero.2025.07.006_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000522","article-title":"Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA\/SLE Network","volume":"8","author":"Deonaraine","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ero.2025.07.006_bib0012","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12882-020-01987-3","article-title":"Adequacy and complication rates of percutaneous renal biopsy with 18- vs. 16-gauge needles in native kidneys in Chinese individuals","volume":"21","author":"Xie","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ero.2025.07.006_bib0013","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1093\/ckj\/sfac150","article-title":"Kidney biopsy in lupus nephritis after achieving clinical renal remission: paving the way for renal outcome assessment","volume":"15","author":"Lled\u00f3-Ib\u00e1\u00f1ez","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ero.2025.07.006_bib0014","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4103\/ijn.ijn_355_21","article-title":"A randomized controlled trial comparing remission induction with modified multitarget therapy with intravenous cyclophosphamide in proliferative lupus nephritis","volume":"33","author":"Pal","year":"2023","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.ero.2025.07.006_bib0015","doi-asserted-by":"crossref","first-page":"e1820","DOI":"10.6061\/clinics\/2020\/e1820","article-title":"Analysis of the clinical effects of the combination of mycophenolate mofetil with either tacrolimus or cyclophosphamide","volume":"75","author":"Zhang","year":"2020","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.ero.2025.07.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.4492","article-title":"Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis: a randomized clinical trial","volume":"5","author":"Zheng","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ero.2025.07.006_bib0017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ero.2025.07.006_bib0018","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ero.2025.07.006_bib0019","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.ero.2025.07.006_bib0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ero.2025.07.006_bib0021","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.ero.2025.07.006_bib0022","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.ero.2025.07.006_bib0023","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.006_bib0024","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.006_bib0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10067-018-4348-z","article-title":"Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial","volume":"38","author":"Zhang","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ero.2025.07.006_bib0026","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s10067-018-4368-8","article-title":"Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study","volume":"38","author":"An","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ero.2025.07.006_bib0027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/1756-185X.14265","article-title":"Ahmedullah AK. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients","volume":"25","author":"Bandhan","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.006_bib0028","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/ijn.IJN_299_18","article-title":"Comparison of two steroid regimens in induction therapy of proliferative lupus nephritis: a randomized controlled trial","volume":"29","author":"Bharati","year":"2019","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.ero.2025.07.006_bib0029","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ero.2025.07.006_bib0030","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2022-222486","article-title":"Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up","volume":"81","author":"Fu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.006_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002686","article-title":"Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial","volume":"8","author":"Wang","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.ero.2025.07.006_bib0032","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/0961203319826690","article-title":"Factors predictive of long-term mortality in lupus nephritis: a multicenter retrospective study of a Japanese cohort","volume":"28","author":"Ichinose","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.ero.2025.07.006_bib0033","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12882-022-02846-z","article-title":"Management practice and treatment outcomes of adult patients with Lupus Nephritis at the Renal Clinic of St. Paul\u2019s Hospital Millennium Medical College, Addis Ababa, Ethiopia","volume":"23","author":"Hailu","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ero.2025.07.006_bib0034","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42358-021-00232-1","article-title":"Proteinuria and serum creatinine after 12 months of treatment for lupus nephritis as predictors of long-term renal outcome: a case-control study","volume":"62","author":"Braga","year":"2022","journal-title":"Adv Rheumatol Lond Engl"},{"key":"10.1016\/j.ero.2025.07.006_bib0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/art.40724","article-title":"Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes","volume":"71","author":"Mackay","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.ero.2025.07.006_bib0036","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/annrheumdis-2020-216965","article-title":"Lack of EULAR\/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis","volume":"79","author":"Moroni","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.006_bib0037","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.3390\/jcm11175017","article-title":"Predictors of early response, flares, and long-term adverse renal outcomes in proliferative lupus nephritis: a 100-month median follow-up of an inception cohort","volume":"11","author":"Kapsia","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ero.2025.07.006_bib0038","first-page":"keae236","article-title":"Risk of chronic kidney disease in 260 patients with lupus nephritis-analysis of a nationwide multicentre cohort with up to 35 years of follow-up","author":"Farinha","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.ero.2025.07.006_bib0039","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","article-title":"Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis","volume":"61","author":"Zen","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.ero.2025.07.006_bib0040","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ekir.2024.01.016","article-title":"Effect of sustained clinical remission on the risk of lupus flares and impaired kidney function in patients with lupus nephritis","volume":"9","author":"Gatto","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ero.2025.07.006_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000533","article-title":"Absence of renal remission portends poor long-term kidney outcome in lupus nephritis","volume":"8","author":"Pirson","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ero.2025.07.006_bib0042","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.006_bib0043","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1007\/s00296-023-05497-x","article-title":"Kidney histopathology in predicting flares following drug withdrawal in proliferative lupus nephritis in clinical remission","volume":"44","author":"Gopal","year":"2024","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ero.2025.07.006_bib0044","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2665-9913(23)00320-X","article-title":"Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial","volume":"6","author":"Chakravarty","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ero.2025.07.006_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000689","article-title":"Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis","volume":"9","author":"Gatto","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ero.2025.07.006_bib0046","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4103\/ijn.IJN_166_19","article-title":"Contribution of clinically indicated repeat renal biopsy in Indian patients with lupus nephritis","volume":"30","author":"Gupta","year":"2020","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.ero.2025.07.006_bib0047","doi-asserted-by":"crossref","first-page":"122","DOI":"10.34067\/KID.0005512021","article-title":"Beyond ISN\/RPS lupus nephritis classification: adding chronicity index to clinical variables predicts kidney survival","volume":"3","author":"Moroni","year":"2022","journal-title":"Kidney"},{"key":"10.1016\/j.ero.2025.07.006_bib0048","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","article-title":"Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis","volume":"97","author":"Malvar","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ero.2025.07.006_bib0049","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1093\/rheumatology\/keaa129","article-title":"Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis","volume":"59","author":"Parodis","year":"2020","journal-title":"Rheumatology (Oxford)"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T15:49:37Z","timestamp":1763308177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S3050708125000606"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.07.006","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of systemic lupus erythematosus with kidney involvement: systematic literature review to inform the 2025 update of EULAR recommendations","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}